Health Canada Approves Abilify LAI For Schizophrenia & Bipolar I Disorder

Otsuka Canada Pharmaceutical Inc. (Otsuka) and Lundbeck Canada Inc. (Lundbeck) announced that Health Canada issued a Notice of Compliance approving use of their long-acting injectable (LAI) formulation ABILIFY ASIMTUFII®, an antipsychotic treatment for schizophrenia and maintenance monotherapy of bipolar I disorder in adults. The medication is a once-every-two-months treatment.

Under the Notice of Compliance, ABILIFY ASIMTUFII can be used without the need to establish treatment adequacy with a shorter-acting LAI. Each dose is provided in a pre-filled syringe and is administered by a health care professional to appropriate patients via intramuscular injection in the . . .